IgA Nephropathy (Berger’s Disease) Study
This clinical trial aims to evaluate the effectiveness of an investigational therapy for IgA Nephropathy, a condition where abnormal immune deposits damage the kidneys' filtering units. The study will assess the therapy’s ability to slow disease progression, reduce protein leakage in the urine, and preserve kidney function.
ELIGIBILITY CRITERIA
We are seeking participants who meet the following criteria:
- Diagnosed with IgA Nephropathy.
- Have measurable protein in their urine.
Study Details
Participants will receive the investigational treatment, undergo regular kidney function tests, and provide blood and urine samples to monitor progress. The study aims to determine if the treatment can delay or prevent the need for dialysis or a kidney transplant.
As part of this paid clinical trial, participants will be compensated for their time and effort, making it an opportunity to contribute to important medical research while earning money.
Do you meet the criteria and want to join the study?
If your child meets the criteria and you are interested in contributing to this important research, they may qualify for this study. For more information or to discuss eligibility, please contact the Haltha team at Haltha Connect.
Take part in live studyUnlock Exclusive Content by Subscribing to Our Updates
Stay informed about the latest advancements, breakthroughs, and trends in medical research
